MX2021013417A - Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. - Google Patents

Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.

Info

Publication number
MX2021013417A
MX2021013417A MX2021013417A MX2021013417A MX2021013417A MX 2021013417 A MX2021013417 A MX 2021013417A MX 2021013417 A MX2021013417 A MX 2021013417A MX 2021013417 A MX2021013417 A MX 2021013417A MX 2021013417 A MX2021013417 A MX 2021013417A
Authority
MX
Mexico
Prior art keywords
clec12a
binding polypeptides
vhh
containing polypeptides
polypeptides
Prior art date
Application number
MX2021013417A
Other languages
English (en)
Inventor
Brendan P Eckelman
John C Timmer
Angelica Sanabria
Lucas Rascon
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of MX2021013417A publication Critical patent/MX2021013417A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se proporcionan polipéptidos que contienen VHH que se unen a CLEC12a, también se proporcionan usos de los polipéptidos que contienen VHH.
MX2021013417A 2019-05-04 2020-05-01 Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos. MX2021013417A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843411P 2019-05-04 2019-05-04
US201962844426P 2019-05-07 2019-05-07
PCT/US2020/030970 WO2020227073A1 (en) 2019-05-04 2020-05-01 Clec12a-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2021013417A true MX2021013417A (es) 2021-12-10

Family

ID=70779935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013417A MX2021013417A (es) 2019-05-04 2020-05-01 Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.

Country Status (11)

Country Link
US (1) US20200347139A1 (es)
EP (1) EP3966243A1 (es)
JP (1) JP2022531306A (es)
KR (1) KR20220004751A (es)
CN (1) CN114127115A (es)
AU (1) AU2020267349A1 (es)
CA (1) CA3138972A1 (es)
IL (1) IL287781A (es)
MX (1) MX2021013417A (es)
SG (1) SG11202111731WA (es)
WO (1) WO2020227073A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3138972A1 (en) * 2019-05-04 2020-11-12 Inhibrx, Inc. Clec12a-binding polypeptides and uses thereof
WO2022099176A1 (en) * 2020-11-09 2022-05-12 2Seventy Bio, Inc. Aml targeted immunotherapies
KR20240004286A (ko) * 2021-04-26 2024-01-11 밀레니엄 파머슈티컬스 인코퍼레이티드 항 Clec12A 항체 및 이의 용도
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
TW202334233A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 結合γδ T細胞之多肽及其用途
WO2023196996A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
CN115772222B (zh) * 2022-12-16 2024-03-29 浙江康佰裕生物科技有限公司 抗cll1单域抗体及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
IL136544A0 (en) 1997-12-05 2001-06-14 Scripps Research Inst Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4994038B2 (ja) 2003-10-22 2012-08-08 ケック グラジュエイト インスティチュート 一倍体接合方法を用いた酵母におけるヘテロ多量体のポリペプチド類の合成方法
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CN101045926A (zh) * 2006-03-27 2007-10-03 上海人类基因组研究中心 人cll1基因、其编码蛋白及应用
US10358492B2 (en) * 2012-09-27 2019-07-23 Merus N.V. Bispecific IgG antibodies as T cell engagers
AU2015292811B2 (en) * 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
EP3693391A1 (en) * 2014-09-12 2020-08-12 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
EP3247407A4 (en) 2015-01-21 2018-08-22 Inhibrx LP Non-immunogenic single domain antibodies
CN107847568B (zh) * 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
EP3405492B1 (en) * 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
WO2020052542A1 (en) * 2018-09-10 2020-03-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against cll1 and constructs thereof
AU2019390483A1 (en) * 2018-11-30 2021-07-15 Aleta Biotherapeutics Inc. Single domain antibodies against CLL-1
CA3138972A1 (en) * 2019-05-04 2020-11-12 Inhibrx, Inc. Clec12a-binding polypeptides and uses thereof
MX2021013590A (es) * 2019-05-08 2022-02-11 Inhibrx Inc Inmunoterapias dirigidas a cll-1.

Also Published As

Publication number Publication date
CN114127115A (zh) 2022-03-01
JP2022531306A (ja) 2022-07-06
US20200347139A1 (en) 2020-11-05
WO2020227073A1 (en) 2020-11-12
EP3966243A1 (en) 2022-03-16
CA3138972A1 (en) 2020-11-12
AU2020267349A1 (en) 2021-11-11
SG11202111731WA (en) 2021-11-29
IL287781A (en) 2022-01-01
KR20220004751A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
MX2021013417A (es) Polipeptidos de union a la proteina del miembro a de la familia 12 del dominio de lectina tipo c (clec12a) y sus usos.
MY194032A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
PH12020500398A1 (en) Antibody-pyrrolobenzodiazepine derivative conjugate
JOP20200074A1 (ar) أجسام مضادة ضد tau واستخداماتها
MX2019007021A (es) Anticuerpos il-11ra.
WO2018081648A8 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
MX2021013416A (es) Polipeptidos de union al antigeno cd33 y sus usos.
NZ725568A (en) Modified j-chain
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
PH12020551716A1 (en) Anti-ror antibody constructs
ZA202106602B (en) Claudin 6 antibodies and uses thereof
IL284561A (en) Neoantigens of the prostate and their uses
MX2018008302A (es) Anticuerpo antigrupo de diferenciacion 9 (anti-cd9) terapeutico.
MX2021002616A (es) Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2).
PH12021550102A1 (en) Cardiosafe antidiabetic therapy
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
MX2021003159A (es) Microemulsiones que contienen antioxidantes.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2021008005A (es) Bibliotecas de peptidos y metodos de uso de las mismas.
MX2019012713A (es) Combinaciones fungicidas.
ZA202005050B (en) Polypeptide, compositions and uses thereof
MX2021015473A (es) Nuevo anticuerpo específico para cthrc1 y su uso.
MX2021004804A (es) Compuestos organolepticos novedosos.